Yin Ophelia Q P, Shi Xiaojin, Tomlinson Brian, Chow Moses S S
School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
J Clin Pharmacol. 2004 Dec;44(12):1412-7. doi: 10.1177/0091270004269760.
The present study determined the interindividual and intrandividual variability of the urinary 6beta-hydroxycortisol/cortisol ratio, a useful marker for CYP3A induction and inhibition in Chinese subjects. The study consisted of 2 parts. In part I, 82 healthy male Chinese subjects underwent 3 study sessions, each separated by a 1-week interval. In part II, 20 subjects who initially completed part I underwent another 3 sessions over a period of 3 to 4 months. During each session, a first-morning urine specimen was collected from each subject for the quantification of urinary concentrations of cortisol and 6beta-hydroxycortisol. There were no significant differences in the mean 6beta-hydroxycortisol/cortisol ratios among the 3 sessions (P > .05, 1-way analysis of variance) for both part I and part II of the study. A normal distribution of the 6beta-hydroxycortisol/cortisol ratio was observed (P = .849, Kolmogorov-Smirnov test). This ratio varied 30-fold (range, 0.76-23.23) among the study subjects. The mean intraindividual variabilities during the short (3-week) and long (3- to 4-month) periods were 30.9% +/- 17.5% and 32.2% +/- 17.1%, respectively. The genetic fraction contributing to the observed variability in the 6beta-hydroxycortisol/cortisol ratio was estimated to be 0.91. The genetic component is likely to contribute significantly to the variability of the 6beta-hydroxycortisol/cortisol ratio, and such variability should be considered when the ratio is used to evaluate CYP3A induction or inhibition in a given ethnic population.
本研究测定了尿6β-羟基皮质醇/皮质醇比值的个体间和个体内变异性,该比值是中国受试者中CYP3A诱导和抑制的有用标志物。该研究包括两部分。在第一部分中,82名健康中国男性受试者进行了3次研究阶段,每个阶段间隔1周。在第二部分中,最初完成第一部分的20名受试者在3至4个月的时间内又进行了3次阶段。在每个阶段,从每个受试者收集首次晨尿标本,用于定量尿中皮质醇和6β-羟基皮质醇的浓度。在研究的第一部分和第二部分中,3个阶段之间的平均6β-羟基皮质醇/皮质醇比值均无显著差异(P>.05,单因素方差分析)。观察到6β-羟基皮质醇/皮质醇比值呈正态分布(P=.849,柯尔莫哥洛夫-斯米尔诺夫检验)。该比值在研究对象中变化了30倍(范围为0.76-23.23)。短期(3周)和长期(3至4个月)期间的平均个体内变异性分别为30.9%±17.5%和32.2%±17.1%。导致观察到的6β-羟基皮质醇/皮质醇比值变异性的遗传因素估计为0.91。遗传成分可能对6β-羟基皮质醇/皮质醇比值的变异性有显著贡献,当该比值用于评估特定种族人群中的CYP3A诱导或抑制时,应考虑这种变异性。